Scholarlink

Background <p>Although Therapeutic Hypothermia in the last two decades promises hope in reducing the problems of asphyxiated babies in developed countries, it is still not available in most parts of the world, and the results available in developing countries are not promising.</p> Objective <p>In this study, we aimed to compare Hypoxic Ischemic Encephalopathy (HIE) infants receiving total hypothermia (TH) and erythropoietin (EPO).</p> Methods <p>In a prospective cohort study, we compared the developmental prognosis of infants with HIE receiving TH (control group, <i>N</i> = 26) with those receiving EPO (case group, <i>N</i> = 34). The severity of acidosis, Apgar score of the first and fifth minutes, seizures, ventilation, and development at the age of two years on the Denver 2 test was compared between two groups.</p> Results <p>The type of delivery, weight, Apgar score in the first minute, and severity of HIE, PH, and HCO3 were homogeneous in the two study groups. No statistically significant difference was observed between the babies in the two study groups in terms of severity of HIE (<i>P</i> = 0.649). Forthy-six percent of the infants in the TH group and 24% of the infants in the EPO group died before age two (<i>P</i> = 0.097). Of the live infants discharged, 24% of the TH group and 35% of the EPO group had developmental delay (<i>P</i> = 0.478). Sixty-five percent of the infants in the TH group and 44% of the EPO group had an unfavorable prognosis at the age of two years (<i>p</i> = 0.123).</p> Conclusions <p>The comparison of TH with EPO prescription in infants with moderate to severe HIE showed that the adverse neurological outcome and death did not show a significant difference between the two groups. Therefore, in areas where TH is not available, the use of erythropoietin as a neuroprotection may be satisfying.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparison of the prognosis of asphyxiated infants receiving hypothermia therapy with those receiving erythropoietin: a prospective cohort study

  • 期刊论文

  • 发表日期：

    2026年2月17日

查看全文
  • Maryam Zakerihamidi,
  • Fatemeh Bagheri,
  • Mohammad Heidarzadeh,
  • Hassan Boskabadi

摘要

Background

Although Therapeutic Hypothermia in the last two decades promises hope in reducing the problems of asphyxiated babies in developed countries, it is still not available in most parts of the world, and the results available in developing countries are not promising.

Objective

In this study, we aimed to compare Hypoxic Ischemic Encephalopathy (HIE) infants receiving total hypothermia (TH) and erythropoietin (EPO).

Methods

In a prospective cohort study, we compared the developmental prognosis of infants with HIE receiving TH (control group, N = 26) with those receiving EPO (case group, N = 34). The severity of acidosis, Apgar score of the first and fifth minutes, seizures, ventilation, and development at the age of two years on the Denver 2 test was compared between two groups.

Results

The type of delivery, weight, Apgar score in the first minute, and severity of HIE, PH, and HCO3 were homogeneous in the two study groups. No statistically significant difference was observed between the babies in the two study groups in terms of severity of HIE (P = 0.649). Forthy-six percent of the infants in the TH group and 24% of the infants in the EPO group died before age two (P = 0.097). Of the live infants discharged, 24% of the TH group and 35% of the EPO group had developmental delay (P = 0.478). Sixty-five percent of the infants in the TH group and 44% of the EPO group had an unfavorable prognosis at the age of two years (p = 0.123).

Conclusions

The comparison of TH with EPO prescription in infants with moderate to severe HIE showed that the adverse neurological outcome and death did not show a significant difference between the two groups. Therefore, in areas where TH is not available, the use of erythropoietin as a neuroprotection may be satisfying.